Physician profile
Daniel T Smith
NPI 1417044751
$2,982.57
in general payments reported to CMS, 2019-2025
24 companies · $607 in 2025
The $607 reported for 2025 was more than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $669 · 2020: $488 · 2021: $113 · 2022: $429 · 2023: $227 · 2024: $450 · 2025: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,284.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $332.90 | 2021-2024 | |
| Paratek Pharmaceuticals, INC. | $326.39 | 2020-2025 | Nuzyra |
| Prodigy Surgical Distribution, INC. | $260.89 | 2020 | |
| Organogenesis INC. | $248.55 | 2019-2025 | Apligraf |
| Advanced Oxygen Therapy INC. | $229.81 | 2019-2020 | |
| Kerecis Limited | $197.46 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Horizon Therapeutics Plc | $162.89 | 2022-2023 | Krystexxa |
| Averitas Pharma INC. | $162.46 | 2024-2025 | Qutenza |
| Integra Lifesciences Corporation | $128.05 | 2019 | |
| Treace Medical Concepts, INC. | $121.18 | 2024-2025 | |
| Mimedx Group, INC. | $118.08 | 2024-2025 | |
| Kci USA, INC. | $106.13 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $96.63 | 2020 | |
| Acell, INC. | $89.76 | 2019 | |
| Smith+Nephew, INC. | $87.51 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aroa Biosurgery Incorporated | $85.11 | 2022 | |
| Amgen INC. | $56.57 | 2024-2025 | Krystexxa |
| Stryker Corporation | $45.99 | 2019 | |
| Depuy Synthes Sales INC. | $32.40 | 2020 | |
| Davol INC. | $27.28 | 2025 | Arista |
| Sandoz INC. | $20.96 | 2020 | |
| Ibsa Pharma INC. | $18.41 | 2025 | Licart, Flector, Tirosint |
| Nabriva Therapeutics, Plc | $14.58 | 2021 | |
| Merck Sharp & Dohme LLC | $12.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.